Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Delivering on the Life Sciences Strategy, One Year On

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.

The Strategy for UK Life Sciences: One Year On report summarises the progress made in the 12 months since the strategy was launched and also announces a number of new measures, including a £20 million investment in regenerative medicine as part of the £600m science capital funding unveiled in the Government’s Autumn Statement earlier this month.

Among the successes has been the establishment of the MRC/Technology Strategy Board Biomedical Catalyst, which so far has committed £49m to 64 projects. This will leverage at least £25m of private sector funding. The Catalyst is designed to support academics and businesses to explore the market potential of their early-stage scientific ideas, and accelerate the development of innovative solutions to healthcare challenges.

The update also highlights recent MRC funding of £7m for 15 research projects awarded through its groundbreaking ‘compound collaboration’ with AstraZeneca. This was the first scheme of its kind, and gave scientists access to 22 AstraZeneca compounds which are now being used by academics to study a broad range of conditions from diseases like Alzheimer’s, cancer and lung disease through to rarer conditions such as motor neurone disease and muscular dystrophies. In November 2012, this ground-breaking initiative won ‘Best Partnership Alliance’ at the annual SCRIP Awards event in London.

Other initiatives by the MRC included in the One Year On report are:

•    An investment of £60m over three years through the MRC Experimental Medicine Challenge Grants. A large number of outline applications have been received and 30 full-stage applications are now being assessed through rigorous international peer review.
•    £9.6m provided for the expansion of UK Biobank. This will include 8,000 brain scans, and one project aims to help scientists discover why some people develop dementia and others do not.
•    An investment of £10.6m in three large-scale collaborative awards under the MRC’s Stratified Medicine Initiative. These stratified medicine consortia will tackle diseases which have a huge impact on patient’s lives – rheumatoid arthritis, hepatitis C and a rare condition called Gaucher disease. This builds on £11.5 investment in pilot consortia focusing on chronic obstructive pulmonary disease, rheumatoid arthritis and diabetes (the MASTERMIND consortia).
•    A joint commitment by the MRC, the Engineering and Physical Sciences Research Council and the Biotechnology and Biological Sciences Research Council to jointly invest £25m over five years to maximise the potential of the Cell Therapy Catapult.
•    A consortium of 10 UK government and charity research funders led by the MRC has awarded £19m to four e-health research Centres of Excellence based in London, Manchester, Dundee and Swansea.
•    The MRC-NIHR Phenome Centre, which will analyse thousands of samples of blood, urine and tissue to discover how our genes interact with our environment to cause and affect the course of disease, will open at Imperial College London in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Laboratory of Molecular Biology Alumni Awarded Nobel Prize for Chemistry
Professor Michael Levitt, Professor Arieh Warshel and Professor Martin Karplus awarded the 2013 Nobel Prize in Chemistry.
Monday, October 14, 2013
MRC and AstraZeneca Scoop Prestigious SCRIP Award
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.
Tuesday, December 04, 2012
Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
Pharmidex to provide all in vivo ADME/PK drug discovery support to the MRCT in 2010.
Thursday, April 15, 2010
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!